- Home
- CIRC vs ACRV Comparison
CIRC vs ACRV Comparison
Compare CIRC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIRC | ACRV |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 74.0M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CIRC | ACRV |
|---|---|---|
| Price | $0.48 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 487.8K | 291.5K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.65 | 15.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,659.00 | N/A |
| Revenue This Year | $10.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $1.27 |
| 52 Week High | $0.98 | $3.56 |
Technical Indicators
Market Signals| Indicator | CIRC | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | N/A |
| Support Level | $0.48 | N/A |
| Resistance Level | $0.80 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 78.84 | 0.00 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.